-

Eurofins Technologies Launches Wastewater Diagnostic Kit for SARS-CoV-2 Testing Including Identification of Omicron Variant

LUXEMBOURG--(BUSINESS WIRE)--Eurofins Technologies announces the launch of the VIRSeek SARS-CoV-2 Mplex I and Mplex II Wastewater real-time RT-PCR kits to provide an efficient solution for SARS-CoV-2 detection in wastewater, including the Omicron variant of concern.

Wastewater-based epidemiology has become an important approach in order to comprehensively monitor the profile of SARS-CoV-2 infections in highly populated areas. Methods to detect SARS-CoV-2 viral RNA in untreated wastewater have advanced over the last number of months. Data has shown that concentrations of viral RNA correlate with trends in reported COVID-19 cases, demonstrating the importance of wastewater testing as a public health tool.

The European Commission has recommended1 the implementation of effective systems for the surveillance of SARS-CoV-2 in wastewater. The VIRSeek SARS-CoV-2 Mplex I and Mplex II Wastewater real-time RT-PCR kits delivers an effective solution for SARS-CoV-2 detection in wastewater. The VIRSeek SARS-CoV-2 Wastewater kits detects genes to specifically identify SARS-CoV-2 together with primer/probes sets to evaluate process parameters such as the nucleic acid extraction efficiency, a specific water quality indicator or the impact of matrix inhibition via an internal positive control. The solution is intended to be used by analytical laboratories for SARS-CoV-2 analysis in wastewater samples as part of quality control/quality assurance testing.

These new members of the VIRSeek real-time RT-PCR kit-family for SARS-CoV-2 detection enhance Eurofins Technologies’ VIRSeek SARS-CoV-2 Solution offering by also enabling the detection of mutant variants such as the Omicron variant of concern. The VIRSeek real-time RT-PCR kit-family also incorporates viral concentration workflow and subsequent lysis and isolation of the viral SARS-CoV-2 RNA, using the VIRSeek RNAExtractor AE1 kit for automated platforms.

More information on Eurofins Technologies website.

About Eurofins Technologies – a fast growing provider of diagnostic technologies in the field of immunoassays and molecular detection methods

Building on the experience and scientific excellence of the Eurofins Group, Eurofins Technologies is a fast growing global provider of diagnostic technologies and industry-leading ELISA-based instruments in the field of bioanalytical testing for the food, feed, environmental, animal health, and clinical diagnostics industries.

About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. With 55,000 staff across a network of 900 laboratories in over 50 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.

Eurofins Shares are listed on Euronext Paris Stock Exchange.

1 https://eur-lex.europa.eu/eli/reco/2021/472/oj

Contacts

Dr. Nadine Göhring
ir@eurofins.com

Eurofins Technologies

BOURSE:ERF


Contacts

Dr. Nadine Göhring
ir@eurofins.com

More News From Eurofins Technologies

The Eurofins Consumer Product Testing Network Completes Significant Laboratory Expansion in Vietnam

HO CHI MINH CITY, Vietnam--(BUSINESS WIRE)--Eurofins Consumer Product Testing Vietnam has completed a major expansion, seeing the laboratory move to a purpose-built 7,000 sq. m laboratory in Ho Chi Minh City. This new facility provides more than two and a half times the floor space of Eurofins Consumer Product Testing Vietnam’s previous site. This investment strengthens the Eurofins Consumer Product Testing network’s capability to deliver world-class testing solutions and supports Vietnam’s rap...

Eurofins: Weekly Report on Share Repurchases From 01st December to 05th December 2025

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins (Paris:ERF): Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 12/01/2025 FR0014000MR3 20 000 58.9527 XPAR EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 12/02/2025 FR0014000MR3 20 000 59.3808 XPAR EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 12/0...

Eurofins Scientific SE: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at 30 November 2025

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (Paris:ERF): ANNEXE B Form to be used for the disclosure of the total number of voting rights and capital, in accordance with the law and grand-ducal regulation of 11 January 2008 on transparency requirements for issuers of securities Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedi (including the issuer ID allocated by the CSSF EUROFINS SCIENTIFIC SE – E1013 Identity of t...
Back to Newsroom